PLRZ
Polyrizon Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$9.69
−3.15%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 306.0K | 342.0K | 118.0K | 4.0K | 5.0K |
| Gross Profit | (306.0K) | (342.0K) | (118.0K) | (4.0K) | (5.0K) |
| Operating Expenses | |||||
| R&D Expense | 4.1M | 2.1M | 534.0K | 332.0K | 347.0K |
| SG&A Expense | 7.7M | 3.8M | 768.0K | 303.0K | 548.0K |
| General & Admin Expense | 2.7M | — | 768.0K | 303.0K | 533.0K |
| Selling & Marketing Expense | — | — | — | — | 15.0K |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 11.8M | 5.9M | 1.3M | 635.0K | 895.0K |
| Cost and Expenses | 12.7M | 6.2M | 1.3M | 635.0K | 895.0K |
| Operating Income (EBIT) | (12.7M) | (6.2M) | (1.3M) | (635.0K) | (895.0K) |
| Non-Operating | |||||
| Interest Income | 2.3M | 370.0K | — | — | — |
| Interest Expense | 7.0K | 3.1M | 3.0K | 2.0K | 2.0K |
| Net Interest Income | 2.4M | (2.8M) | (28.0K) | (230.0K) | (2.0K) |
| Other Non-Op Income/Expense | 7.3M | 2.9M | (243.0K) | 35.0K | 116.0K |
| Non-Operating Income (excl Interest) | — | — | 240.0K | (37.0K) | (118.0K) |
| EBT (Pre-Tax Income) | (5.5M) | (3.3M) | (1.5M) | (600.0K) | (779.0K) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (5.5M) | (3.3M) | (1.5M) | (600.0K) | (779.0K) |
| Earnings from Cont. Ops | (5.5M) | (3.3M) | (1.5M) | (600.0K) | (779.0K) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (6.9M) | (3.3M) | (1.6M) | (669.0K) | (823.0K) |
| Per Share | |||||
| Basic EPS | ($4.55) | ($2.07) | ($134.14) | $0.00 | $0.00 |
| Diluted EPS | ($4.55) | ($2.07) | ($134.14) | $0.00 | $0.00 |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Shares | |||||
| Basic Shares Outstanding | 1.8M | 1.6M | 11000 | 2796 | — |
| Diluted Shares Outstanding | 1.8M | 1.6M | 11965 | 2796 | — |
| Profitability Metrics | |||||
| EBITDA | (12.3M) | (5.9M) | (1.4M) | (631.0K) | (772.0K) |
| D&A | 459.0K | 342.0K | 118.0K | 4.0K | 5.0K |
| EBIT | (12.7M) | (6.2M) | (1.5M) | (635.0K) | (777.0K) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026